A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
Nowak R, Benatar M, Ciafaloni E, Howard J, Leite M, Utsugisawa K, Vissing J, Rojavin M, Li Q, Tang F, Wu Y, Rampal N, Cheng S. A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis. New England Journal Of Medicine 2025, 392: 2309-2320. PMID: 40202593, DOI: 10.1056/nejmoa2501561.Peer-Reviewed Original ResearchConceptsAcetylcholine receptor antibody-positivePhase 3 trialMyasthenia gravisMyasthenia Gravis ActivitiesAdverse eventsAntibody-positiveQuantitative myasthenia gravis scaleIncidence of serious adverse eventsCD19+ B cellsAnti-acetylcholine receptor antibodiesHigher incidenceAnti-muscle-specific kinase antibodiesInfusion-related reactionsMG-ADL scoresPlacebo-controlled trialUrinary tract infectionGeneralized myasthenia gravisSerious adverse eventsQMG scoreGlucocorticoid therapyDouble-blindReceptor antibodiesTract infectionsInebilizumabAnti-acetylcholine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply